313 related articles for article (PubMed ID: 7902089)
1. The efflux of anthracyclines in multidrug-resistant cell lines.
Coley HM; Twentyman PR; Workman P
Biochem Pharmacol; 1993 Oct; 46(8):1317-26. PubMed ID: 7902089
[TBL] [Abstract][Full Text] [Related]
2. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A.
Coley HM; Twentyman PR; Workman P
Biochem Pharmacol; 1989 Dec; 38(24):4467-75. PubMed ID: 2604747
[TBL] [Abstract][Full Text] [Related]
3. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance.
Coley HM; Twentyman PR; Workman P
Anticancer Drug Des; 1992 Dec; 7(6):471-81. PubMed ID: 1337431
[TBL] [Abstract][Full Text] [Related]
4. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.
Coley HM; Amos WB; Twentyman PR; Workman P
Br J Cancer; 1993 Jun; 67(6):1316-23. PubMed ID: 8099807
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
[TBL] [Abstract][Full Text] [Related]
6. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
Lehne G; De Angelis P; Clausen OP; Rugstad HE
Br J Cancer; 1996 Dec; 74(11):1719-29. PubMed ID: 8956784
[TBL] [Abstract][Full Text] [Related]
7. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression.
Coley HM; Workman P; Twentyman PR
Br J Cancer; 1991 Mar; 63(3):351-7. PubMed ID: 1672252
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
[TBL] [Abstract][Full Text] [Related]
9. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Mülder HS; Dekker H; Pinedo HM; Lankelma J
Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
[TBL] [Abstract][Full Text] [Related]
10. Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A.
Coley HM; Twentyman PR; Workman P
Cancer Chemother Pharmacol; 1989; 24(5):284-90. PubMed ID: 2547527
[TBL] [Abstract][Full Text] [Related]
11. 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance.
Coley HM; Twentyman PR; Workman P
Eur J Cancer; 1990; 26(6):665-7. PubMed ID: 1975502
[TBL] [Abstract][Full Text] [Related]
12. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
13. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.
Dale IL; Tuffley W; Callaghan R; Holmes JA; Martin K; Luscombe M; Mistry P; Ryder H; Stewart AJ; Charlton P; Twentyman PR; Bevan P
Br J Cancer; 1998 Oct; 78(7):885-92. PubMed ID: 9764579
[TBL] [Abstract][Full Text] [Related]
14. Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells.
Lopes EC; Scolnik M; Alvarez E; Hajos SE
Leuk Res; 2001 Jan; 25(1):85-93. PubMed ID: 11137565
[TBL] [Abstract][Full Text] [Related]
15. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes.
Twentyman PR; Rhodes T; Rayner S
Eur J Cancer; 1994; 30A(9):1360-9. PubMed ID: 7999426
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
17. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Mankhetkorn S; Garnier-Suillerot A
Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
[TBL] [Abstract][Full Text] [Related]
18. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells.
Sehested M; Bindslev N; Demant EJ; Skovsgaard T; Jensen PB
Biochem Pharmacol; 1989 Sep; 38(18):3017-27. PubMed ID: 2571333
[TBL] [Abstract][Full Text] [Related]
19. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
Benderra Z; Trussardi A; Morjani H; Villa AM; Doglia SM; Manfait M
Eur J Cancer; 2000 Feb; 36(3):428-34. PubMed ID: 10708946
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.
Nielsen D; Maare C; Skovsgaard T
Biochem Pharmacol; 1994 Jun; 47(12):2125-35. PubMed ID: 7913318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
